Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

458.94 +10.34 (+2.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,315,490
Open 452.03
Bid (Size) 451.52 (1)
Ask (Size) 465.35 (1)
Prev. Close 448.60
Today's Range 451.11 - 459.87
52wk Range 341.93 - 510.63
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By 'Strong AI Demand' And 'Margin Expansion'
Goldman Sachs raises S&P 500's EPS forecast to $268 in 2025, driven by AI tech demand & semiconductor recovery. Margin expansion & macro growth fuel optimism for tech & healthcare sectors. 
Via Benzinga
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Insider Trades: How To Find The Top Stocks
There are dozens of insider trades going on every week. Here are 5 insider stock buys that stand out. 
Via Talk Markets

Performance

YTD
+11.69%
+11.69%
1 Month
-2.58%
-2.58%
3 Month
-4.76%
-4.76%
6 Month
+13.54%
+13.54%
1 Year
+29.21%
+29.21%

More News

Read More
3 Top Stocks That Could Still Rocket Higher in 2024
Via The Motley Fool
2 Superior Growth Stocks That Are Screaming Buys Right Now
Via The Motley Fool
What Analysts Are Saying About Vertex Pharmaceuticals Stock
Via Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,200 Today
Via Benzinga
Demystifying Vertex Pharmaceuticals: Insights From 16 Analyst Reviews
Via Benzinga
Looking Into Vertex Pharmaceuticals's Recent Short Interest
Via Benzinga
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
Via Investor's Business Daily
Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
The Best Biotech Stock to Invest $1,000 in Right Now
Via The Motley Fool
Bull Market and Beyond: 2 Stocks Just Waiting to Soar
Via The Motley Fool
Vertex Pharmaceuticals's Options Frenzy: What You Need to Know
Via Benzinga
Looking Into Vertex Pharmaceuticals's Recent Short Interest
Via Benzinga
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
Via The Motley Fool
3 Stocks to Buy and Hold Forever
Via The Motley Fool
Prediction: These 3 Phenomenal Stocks Are Set to Soar
Via The Motley Fool
Time To Invest And Or Trade In Bio-Tech Stocks?
Via Talk Markets
Topics ETFs
Biotech Breakout: Stocks for Your Watchlist
Via MarketBeat
Topics ETFs
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years
Via Benzinga
3 No-Brainer Stocks to Buy in September
Via The Motley Fool
3 Rock-Solid Pharma Stocks to Buy Now and Hold Forever
Via The Motley Fool
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
Via The Motley Fool
Biotech And Life Science Sector Update Summer Of 2024
Via Talk Markets
Jim Cramer: 'Hold On' To Builders FirstSource, 'Here's The Problem' With Viking Therapeutics
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.